{"id":3821,"date":"2023-06-13T19:00:12","date_gmt":"2023-06-14T00:00:12","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=3821"},"modified":"2023-06-13T19:00:16","modified_gmt":"2023-06-14T00:00:16","slug":"next-covid-vaccine-should-only-target-xbb-strains-fda-staff-says","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2023\/06\/13\/next-covid-vaccine-should-only-target-xbb-strains-fda-staff-says\/","title":{"rendered":"Next COVID Vaccine Should Only Target XBB Strains, FDA Staff Says"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p><a href=\"https:\/\/www.medpagetoday.com\/infectiousdisease\/covid19vaccine\/104996\">MedPageToday<\/a> <\/p>\n\n\n\n<p>The next COVID vaccines should exclude the original strain of SARS-CoV-2 and exclusively target the Omicron XBB subvariants, according to FDA staff members.<\/p>\n\n\n\n<p>They unveiled their recommendation in a\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/www.fda.gov\/media\/169378\/download\" target=\"_blank\">briefing document<\/a>\u00a0ahead of Thursday&#8217;s meeting of the FDA&#8217;s\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/vaccines-and-related-biological-products-advisory-committee-june-15-2023-meeting-announcement\" target=\"_blank\">Vaccines and Related Biological Products Advisory Committee (VRBPAC)<\/a>, stating that &#8220;the totality of available evidence suggests that a monovalent XBB-lineage vaccine is warranted for the 2023-2024 vaccination campaign.&#8221; <\/p>\n\n\n\n<p>XBB strains are\u00a0more immune evasive\u00a0than prior Omicron subvariants and currently account for about 95% of COVID-19 cases worldwide, the agency staffers noted.<\/p>\n\n\n\n<p>In the U.S., eight XBB strains account for over 98% of the current cases, according to\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions\" target=\"_blank\">CDC&#8217;s Nowcast<\/a>\u00a0tracker, including three sublineages under consideration for the fall vaccine:\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/www.medpagetoday.com\/special-reports\/features\/102496\" target=\"_blank\">XBB.1.5<\/a>\u00a0in 40%, and the newer\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/www.medpagetoday.com\/infectiousdisease\/covid19\/103862\" target=\"_blank\">XBB.1.16<\/a>\u00a0in 18% and XBB.2.3 in 6% of cases.<\/p>\n\n\n\n<p>Spike proteins of these three sublineages &#8220;are similar with few amino acid differences &#8230; and available studies suggest little to no further immune evasion from these new substitutions in the XBB.1.16 spike compared to XBB.1.5,&#8221; noted FDA staff.<\/p>\n<!-- <a rel=\"nofollow\" href=\"\/secure-location.php\" title=\"h d  pW RcstOW\">h d  pW RcstOW<\/a> --><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>MedPageToday The next COVID vaccines should exclude the original strain of SARS-CoV-2 and exclusively target the Omicron XBB subvariants, according to FDA staff members. They unveiled their recommendation in a\u00a0briefing document\u00a0ahead of Thursday&#8217;s meeting of the FDA&#8217;s\u00a0Vaccines and Related Biological Products Advisory Committee (VRBPAC), stating that &#8220;the totality of available evidence suggests that a monovalent [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[8],"tags":[],"class_list":["post-3821","post","type-post","status-publish","format-standard","hentry","category-vaccine-headlines"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=3821"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3821\/revisions"}],"predecessor-version":[{"id":3822,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3821\/revisions\/3822"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=3821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=3821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=3821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}